Conclusions
RUBELLA
This study documented non-inferior seroconversion with co-administration of MMR and YF vaccines for all antigens when compared with individual administration in our ITT population. However, co-administration resulted in significantly lower antibody levels for rubella and YF compared with the values seen with individual administration. The data generated from this study have already contributed to a global policy recommendation. The WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) reviewed the results from this study, along with the studies in Brazil and The Gambia and data on the impact of vaccination schedules on coverage, and decided to retain their recommendation that live, attenuated vaccines can be either co-administered or provided at least four weeks apart from each other [